# Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

> **NCT07208981** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 169 (estimated)

## Conditions studied

- Marginal Zone Lymphoma(MZL)

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Zebetuzumab
- **DRUG:** Lenalidomide
- **DRUG:** Bendamustine + Rituximab

## Key facts

- **NCT ID:** NCT07208981
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-14
- **Primary completion:** 2028-06-01
- **Final completion:** 2031-06-01
- **Target enrollment:** 169 (ESTIMATED)
- **Last updated:** 2025-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07208981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07208981, "Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07208981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*